Pharma Business - December 4, 2014
Pay-to-Delay Could Cost AZ Billions
AstraZeneca potentially could face billions of dollars in damages if it loses its “pay-to-delay” case currently in US. federal court in Boston. The case involves a 2008 settlement AstraZeneca reached with India’s Ranbaxy Laboratories to hold off on bringing to market a generic of its heartburn medication Nexium. The plaintiffs, which represent pharmacies, wholesalers and consumers, contend […]
Acquisition - November 25, 2014
AZ Plans U.S. Expansion
AstraZeneca plans to kick off a U.S. expansion anticipated to add 300 jobs so it can capitalize on a pipeline full of strong candidates, which it is counting on to help return the company to growth by 2017. “Our global biologics research and development arm, MedImmune, has a robust pipeline of more than 120 biologics, […]
Drug Development Pharma - November 19, 2014
AstraZeneca Officials Optimistic
AstraZeneca officials are feeling positive about the future, with enough drugs in production to fuel double-digit submissions and approvals by 2017, reaffirming its promise to grow sales by 75 percent. The company has 14 Phase III drugs that will account for eight-to-ten approvals over the next two years. Leading the way is the company’s revitalized […]
Drug Development Pharma - November 14, 2014
AZ Developing Blood-Thinner Antidote
While sales of AstraZeneca’s blood-thinner Brilinta have been growing, the company has started a preclinical development program on a potential Brilinta antidote, now known as MEDI2452. If it works, the antidote could quickly reverse the effects of the blood thinner in an emergency, such as a person having a major bleeding episode. Doctors would not […]
Acquisition - November 7, 2014
MedImmune Acquires Definiens
MedImmune, AstraZeneca’s global biologics research and development arm, has entered into an agreement to acquire Definiens, a privately-held company that has developed an imaging and data analysis technology known as Tissue Phenomics™. The new technology significantly improves the identification of biomarkers in tumor tissue. According to the agreement, MedImmune will acquire 100 percent of Definiens’ […]
Pharma article - November 5, 2014
AZ’s Healthy Heart Africa
AstraZeneca’s new Healthy Heart Africa program is aimed at increasing awareness of the symptoms and risks of hypertension among vulnerable populations in Africa. Initially launching in Kenya, the program will provide education, screening, treatment and methods to control hypertension. AstraZeneca is collaborating with non-government organizations from Kenya and other countries to offer support to local […]
